POINT RICHMOND, Calif., Nov. 26, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced that it will host a conference call to discuss the broadened Intermezzo® commercialization strategy and consumer advertising campaign by Purdue Pharmaceutical Products, L.P.
Conference Call InformationDate: Tuesday, November 27, 2012Time: 8:30 a.m. ETDial-in (U.S.): 877-638-4558Dial-in (International): 914-495-8537
A simultaneous web cast of the conference call will be available on the Investors section of the Transcept website at www.transcept.com. A replay of the call will be available on the website shortly after the conclusion of the call until January 30, 2013.
About TransceptTranscept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue Pharma holds commercialization and development rights for Intermezzo in
the United States. Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. For further information about Transcept, please visit
www.transcept.com. For information about Intermezzo, please visit
Contact:Transcept Pharmaceuticals, Inc. Greg MannSr. Director, Corporate Communications(510) 215-3567 firstname.lastname@example.org